JP2017529859A5 - - Google Patents

Download PDF

Info

Publication number
JP2017529859A5
JP2017529859A5 JP2017517098A JP2017517098A JP2017529859A5 JP 2017529859 A5 JP2017529859 A5 JP 2017529859A5 JP 2017517098 A JP2017517098 A JP 2017517098A JP 2017517098 A JP2017517098 A JP 2017517098A JP 2017529859 A5 JP2017529859 A5 JP 2017529859A5
Authority
JP
Japan
Prior art keywords
single nucleotide
breast cancer
risk
female subject
linkage disequilibrium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017517098A
Other languages
English (en)
Japanese (ja)
Other versions
JP6820838B2 (ja
JP2017529859A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2015/050583 external-priority patent/WO2016049694A1/en
Publication of JP2017529859A publication Critical patent/JP2017529859A/ja
Publication of JP2017529859A5 publication Critical patent/JP2017529859A5/ja
Application granted granted Critical
Publication of JP6820838B2 publication Critical patent/JP6820838B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017517098A 2014-09-30 2015-09-29 乳癌発症リスクを評価する方法 Expired - Fee Related JP6820838B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014903898 2014-09-30
AU2014903898A AU2014903898A0 (en) 2014-09-30 Methods for assessing the risk of developing breast cancer
PCT/AU2015/050583 WO2016049694A1 (en) 2014-09-30 2015-09-29 Methods for assessing risk of developing breast cancer

Publications (3)

Publication Number Publication Date
JP2017529859A JP2017529859A (ja) 2017-10-12
JP2017529859A5 true JP2017529859A5 (https=) 2018-11-08
JP6820838B2 JP6820838B2 (ja) 2021-01-27

Family

ID=55629155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017517098A Expired - Fee Related JP6820838B2 (ja) 2014-09-30 2015-09-29 乳癌発症リスクを評価する方法

Country Status (11)

Country Link
US (2) US10920279B2 (https=)
EP (1) EP3201360A4 (https=)
JP (1) JP6820838B2 (https=)
KR (1) KR102334702B1 (https=)
CN (1) CN107002138B (https=)
AU (2) AU2015327756B2 (https=)
CA (1) CA2962691C (https=)
IL (1) IL251376B (https=)
MX (1) MX392267B (https=)
SG (1) SG11201702416YA (https=)
WO (1) WO2016049694A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2631621C (en) 2005-11-29 2019-08-06 Cambridge Enterprise Limited Markers for breast cancer including rs2981582
US20110294681A1 (en) 2009-06-01 2011-12-01 Hinds David A Methods for breast cancer risk assessment
US10920279B2 (en) 2014-09-30 2021-02-16 Genetic Technologies Limited Method for modifying a treatment regimen of a human female subject
JP2020508643A (ja) * 2017-01-24 2020-03-26 ジェネティック テクノロジーズ リミテッド 乳癌発症リスクの改良された評価法
US12577622B2 (en) 2017-06-02 2026-03-17 Myriad Genetics, Inc. Detecting cancer risk
US20200354797A1 (en) * 2017-10-13 2020-11-12 Genetic Technologies Limited Methods of assessing risk of developing breast cancer
CN108060229A (zh) * 2017-12-27 2018-05-22 沃森克里克(北京)生物科技有限公司 一种TERT基因rs10069690位点SNP核酸质谱检测方法
CN110628912A (zh) * 2019-11-06 2019-12-31 上海韦翰斯生物医药科技有限公司 检测多态性的引物及方法
KR102169699B1 (ko) * 2019-12-27 2020-10-23 주식회사 클리노믹스 유전자 검사를 위한 맞춤형 유전자칩 및 이의 제작 방법
EP4158067A4 (en) * 2020-05-27 2024-09-25 Genetic Technologies Limited Methods of assessing risk of developing a severe response to coronavirus infection
CN112687330A (zh) * 2020-12-29 2021-04-20 北京易奇科技有限公司 一种乳腺癌患者携带胚系致病变异的风险预测系统
CN114283883B (zh) * 2021-12-27 2022-11-22 上海华测艾普医学检验所有限公司 基于分子标记的用于肝癌筛查和风险预测的系统及应用
US20250149176A1 (en) * 2023-11-08 2025-05-08 Optum Services (Ireland) Limited Model-based risk prediction and treatment pathway prioritization

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54147035A (en) 1978-05-10 1979-11-16 Minolta Camera Co Ltd Tessar type photographic lens placed behind aperture
US4240608A (en) 1979-11-02 1980-12-23 Acf Industries, Incorporated Controlled float seat arrangement for expanding gate valves
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
JPH09507121A (ja) 1993-10-26 1997-07-22 アフィマックス テクノロジーズ ナームロゼ ベノートスハップ 生物学的チップ上の核酸プローブアレー
EP1033411B1 (en) 1996-06-04 2006-02-22 University of Utah Research Foundation Fluorescent donor-acceptor pair
DE69704031T2 (de) 1996-11-07 2001-06-13 Oklahoma Medical Research Foundation, Oklahoma Test zur diagnose eines erhöhten brustkrebs-risikos
AU3108200A (en) 1998-12-02 2000-06-19 Kiva Genetics, Inc. Methods to reduce variance in treatment studies using genotyping
US20020123095A1 (en) 1999-10-20 2002-09-05 Pe Corporation (Ny) Estrogen receptor alpha variants and methods of detection thereof
EP1305446A4 (en) 2000-07-25 2004-10-06 Dz Genes Llc DIAGNOSIS OF ECNOS PROMOTER POLYMORPHISMS
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030092019A1 (en) 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
AU785425B2 (en) 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
AU2002322775A1 (en) 2001-07-27 2003-02-17 The Regents Of The University Of California Stk15 (stk6) gene polymorphism and methods of determining cancer risk
US7529685B2 (en) 2001-08-28 2009-05-05 Md Datacor, Inc. System, method, and apparatus for storing, retrieving, and integrating clinical, diagnostic, genomic, and therapeutic data
WO2003025141A2 (en) 2001-09-19 2003-03-27 Intergenetics Incorporated Genetic analysis for stratification of cancer risk
US20040023237A1 (en) 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
US6897025B2 (en) 2002-01-07 2005-05-24 Perlegen Sciences, Inc. Genetic analysis systems and methods
US7135286B2 (en) 2002-03-26 2006-11-14 Perlegen Sciences, Inc. Pharmaceutical and diagnostic business systems and methods
US7427480B2 (en) 2002-03-26 2008-09-23 Perlegen Sciences, Inc. Life sciences business systems and methods
US20040210400A1 (en) 2003-01-27 2004-10-21 Perlegen Sciences, Inc. Analysis methods for individual genotyping
US20040191783A1 (en) 2003-03-31 2004-09-30 Guy Leclercq Low density micro-array analysis in human breast cancer
US20050019787A1 (en) 2003-04-03 2005-01-27 Perlegen Sciences, Inc., A Delaware Corporation Apparatus and methods for analyzing and characterizing nucleic acid sequences
US7124033B2 (en) 2003-04-30 2006-10-17 Perlegen Sciences, Inc. Method for identifying matched groups
US20040229224A1 (en) 2003-05-13 2004-11-18 Perlegen Sciences, Inc. Allele-specific expression patterns
US20040241657A1 (en) 2003-05-28 2004-12-02 Perlegen Sciences, Inc. Liver related disease compositions and methods
WO2005014846A2 (en) * 2003-07-24 2005-02-17 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
US20050136438A1 (en) 2003-09-04 2005-06-23 David Ralph Genetic analysis for stratification of cancer risk
US7127355B2 (en) 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
US20090087854A1 (en) 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
CA2631621C (en) 2005-11-29 2019-08-06 Cambridge Enterprise Limited Markers for breast cancer including rs2981582
EP2207895A2 (en) 2006-06-23 2010-07-21 InterGenetics, Inc. Genetic models for stratification of cancer risk
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
EA019953B1 (ru) * 2007-03-26 2014-07-30 Декоуд Дженетикс Ехф Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
CA2688312A1 (en) 2007-05-25 2008-12-04 Decode Genetics Ehf. Genetic variants on chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
US20090029375A1 (en) 2007-07-11 2009-01-29 Intergenetics, Inc. Genetic models for stratification of cancer risk
WO2009097270A2 (en) * 2008-01-28 2009-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of determining breast cancer risk
GB2478065A (en) 2008-08-08 2011-08-24 Navigenics Inc Method and systems for personalized action plans
KR20110074527A (ko) 2008-09-12 2011-06-30 네이비제닉스 인크. 복수의 환경 및 유전 위험 인자를 통합하기 위한 방법 및 시스템
US20110294681A1 (en) * 2009-06-01 2011-12-01 Hinds David A Methods for breast cancer risk assessment
AU2010265889A1 (en) * 2009-06-25 2012-01-19 Yale University Single nucleotide polymorphisms in BRCA1 and cancer risk
WO2013151413A1 (en) * 2012-04-02 2013-10-10 Infovalley Life Science Sdn. Bhd. Methods and compositions for determining increased risk for breast cancer
US10920279B2 (en) 2014-09-30 2021-02-16 Genetic Technologies Limited Method for modifying a treatment regimen of a human female subject
JP2020508643A (ja) 2017-01-24 2020-03-26 ジェネティック テクノロジーズ リミテッド 乳癌発症リスクの改良された評価法
US10609708B1 (en) 2017-06-27 2020-03-31 Sprint Spectrum L.P. Use of TDD special subframe for transmission of small quantity of data
US20200354797A1 (en) 2017-10-13 2020-11-12 Genetic Technologies Limited Methods of assessing risk of developing breast cancer

Similar Documents

Publication Publication Date Title
JP2017529859A5 (https=)
Fehlmann et al. Evaluating the use of circulating microRNA profiles for lung cancer detection in symptomatic patients
ES2962775T3 (es) Método para predecir el pronóstico de pacientes con cáncer de mama
JP7452894B2 (ja) 遺伝子のcpgメチル化変化を用いた肝癌の予後または危険度を評価する方法
Zhang et al. Comprehensive one-step molecular analyses of mitochondrial genome by massively parallel sequencing
JP2018505658A5 (https=)
CA2978442A1 (en) Methods for assessing the risk of disease occurrence or recurrence using expression level and sequence variant information
Rodriguez-Reyna et al. HLA class I and II blocks are associated to susceptibility, clinical subtypes and autoantibodies in Mexican systemic sclerosis (SSc) patients
JP6606554B2 (ja) Y染色体のメチル化部位を前立腺ガンの診断用マーカとする使用
CN104178567B (zh) 一种与乳腺癌辅助诊断相关的snp标志物及其应用
CN108323184A (zh) 验证生物标志物测量
JP2019510473A5 (https=)
CN106591438A (zh) 一种用于检测Her2基因的核酸组合、试剂盒及应用
JP2021502069A5 (https=)
CN106148529A (zh) 与胃癌相关的LncRNA标记物及其专用检测引物、检测方法、试剂盒与应用
Xin et al. Clinical potential of TCF21 methylation in the diagnosis of renal cell carcinoma
CN104293919A (zh) 一种与非吸烟女性肺癌辅助诊断相关的snp标志物及其应用
CN103911440B (zh) 一种与铂类化疗药物肝脏毒性相关的snp标志物及其应用
CN114990215A (zh) microRNA生物标志物在肺癌诊断或预测预后中的应用
JP5461959B2 (ja) 神経膠腫予後予測方法、およびそれに用いるキット
WO2016066797A2 (en) Ovarian cancer prognostic subgrouping
RU2440415C1 (ru) Набор синтетических олигонуклеотидов для определения нуклеотидной последовательности кодирующей части гена brca1 и выявления мутаций, ассоциированных с наследственными формами рака молочной железы
US12371749B2 (en) Molecular pathogenesis of microcarcinoma of the thyroid
CN105087758A (zh) 一种肺癌预后预测miRNA检测试剂盒
KR102161511B1 (ko) 담도암 진단용 바이오마커의 추출 방법, 이를 위한 컴퓨팅 장치, 담도암 진단용 바이오마커 및 이를 포함하는 담도암 진단 장치